Purinergic Signalling: Nucleotide/Nucleoside Receptor Pharmacology
Purinergic signalling system (extracellular nucleotides/nucleosides as intercellular signals; released by: cell damage/necrosis (passive ATP release), exocytosis (vesicular ATP co-release with neurotransmitters), pannexin-1/connexin-43 hemichannels (NLRP3/P2X7-induced), ATP-binding cassette transporters (ABCC4/5)); receptors: P2 receptors (activated by extracellular ATP/ADP/UTP/UDP): P2X (ligand-gated ion channels; 7 subtypes; homotrimers/heterotrimers; fast Ca2+/Na+/K+ flux; P2X7 (macrophage/microglia/osteoclast; low-affinity ATP receptor (EC50 ~100 µM; requires high local ATP → damage signal); activation → pannexin-1 pore → K+ efflux → NLRP3; sustained activation → large pore formation → dye uptake → cell death; regulated by extracellular Mg2+/Zn2+); P2X3 (sensory neuron; pain)); P2Y (GPCRs; 8 subtypes; P2Y1/P2Y12 (platelet ADP receptors; Gi-coupled; adenylyl cyclase ↓ → reduced cAMP → platelet activation; P2Y12 is clopidogrel/ticagrelor target)); P1 receptors (adenosine; 4 subtypes; A1 (Gi; heart rate ↓; neuronal inhibition), A2A (Gs → cAMP ↑ → PKA → anti-inflammatory: T cell suppression, macrophage IL-10 ↑, TNF-α ↓; also cAMP → eNOS → NO → vasodilation), A2B (Gs → cAMP; low-affinity; ischaemic preconditioning), A3 (Gi; mast cell activation; cardioprotection)); ectonucleotidases: ATP → ADP → AMP (CD39/NTPDase1/2/3/8; ecto-apyrase; Ca2+/Mg2+-dependent) → adenosine (CD73/5′-nucleotidase (ecto-5′NT); GPI-anchored; AMP → adenosine + Pi); adenosine uptake: ENT1/2 (equilibrative nucleoside transporters; concentrative gradient); adenosine kinase (AK; adenosine → AMP; intracellular; low Km; major adenosine-degrading enzyme).
Spirulina Mechanisms in Purinergic Signalling
Intracellular AMP:ATP Elevation and Adenosine Precursor
AMPK activation by spirulina (phycocyanin mild Complex I modulation → AMP:ATP ↑ → LKB1-AMPK Thr172 phosphorylation) simultaneously elevates intracellular AMP as an adenosine precursor: elevated intracellular AMP → (1) cytoplasmic 5′-nucleotidase (cN-I/cN-II; AMP → adenosine → ENT1/2 export → extracellular adenosine; or adenosine deaminase (ADA) → inosine → hypoxanthine → xanthine → uric acid); (2) purine nucleotide cycling: AMP → adenylosuccinate (ADSS) → AMP regeneration; excess AMP → deamination (AMP deaminase/AMPD → IMP); AMPD regulation: AMPD3 in erythrocytes/heart; AMPD2 ubiquitous; during exercise: AMPD1 skeletal muscle → IMP → hypoxanthine → xanthine (XOR/XDH → uric acid/ROS; spirulina xanthine analogue mild XOR inhibition reduces this ROS-generating arm); the spirulina-AMPK → AMP elevation pathway provides adenosine precursor for CD73-mediated extracellular production and A2A receptor anti-inflammatory signalling. In exercise: spirulina blunts AMP → AMPD → IMP → uric acid pathway (−10–20% post-exercise uric acid) while maintaining AMPK metabolic signalling.
CD39/CD73 Ectonucleotidase Upregulation
CD39 (NTPDase1; ENTPD1; converts extracellular ATP/ADP → AMP; expressed on Treg cells, endothelium, activated DCs; converts pro-inflammatory ATP → anti-inflammatory AMP/adenosine) and CD73 (5′-ecto-nucleotidase; NT5E; AMP → adenosine; expressed on lymphocytes, endothelium, stroma; CD73-derived adenosine is the primary local anti-inflammatory adenosine source at inflammation sites; CD73 knockout → exaggerated inflammation; A2A agonism mimics CD73 effects) are upregulated by spirulina through: (1) Nrf2/ARE: CD73 promoter contains functional ARE element; Nrf2 activation → CD73 +15–25% in endothelial and immune cell models; (2) AMPK: AMPK promotes Treg phenotype (FoxP3+ Treg CD39/CD73 expression; AMPK → mTORC1 ↓ → Treg/Th17 balance towards Treg) → CD39 +10–20% on Treg; (3) IL-10 (spirulina → IL-10 +10–20%) → CD73 upregulation on macrophages (IL-10 → STAT3 → CD73 transcription); net: extracellular adenosine production at inflammatory sites +15–25% in spirulina-supplemented models.
A2A Receptor Anti-Inflammatory cAMP Signalling
A2A receptor (adenosine A2A; Gs-coupled; high expression: striatum (Parkinson's target: istradefylline/caffeine antagonists), T cells, macrophages, endothelium; activation: adenosine binding → Gs → adenylyl cyclase → cAMP ↑ → PKA → (1) T cell: cAMP → PKA → Lck Tyr394 inhibition → TCR signalling ↓ → T cell suppression (physiological immune regulation; tumour microenvironment A2A → CD8+ T cell exhaustion; problematic in cancer but beneficial in autoimmune); (2) macrophage: cAMP → PKA → NF-κB ↓ + CREB ↑ → IL-10 ↑, TNF-α ↓, IL-12 ↓; (3) endothelium: cAMP → eNOS Ser633 phosphorylation (PKA site) → NO → vasodilation + anti-thrombotic)) is amplified by spirulina through: (1) elevated extracellular adenosine (CD73 ↑) → more A2A ligand; (2) PDE inhibition: phycocyanin mild PDE (−10–20% PDE activity) → cAMP/cGMP pool elevated → A2A-generated cAMP longer-lived → PKA signalling prolonged; (3) cAMP → eNOS convergence: both A2A-cAMP-PKA-eNOS Ser633 and spirulina AMPK-eNOS Ser1177 activate eNOS; synergistic NO production; (4) A2A/A2B → FoxO3a Ser253 dephosphorylation → FoxO3a nuclear → Mn-SOD transcription (antioxidant).
P2X7-NLRP3 Gate Attenuation
P2X7-NLRP3 axis (extracellular ATP (damage signal from necrosis) → P2X7 → K+ efflux (primary NLRP3 activation trigger) + pannexin-1 pore → NLRP3 assembly → caspase-1 → IL-1β/pyroptosis; P2X7 antagonists (AZ11645373, A-438079) block NLRP3 activation; P2X7 Cys17/Cys23 are S-nitrosylation targets: NO → P2X7 Cys → reduced ion channel open probability)) is attenuated by spirulina through: (1) eNOS-NO pathway: spirulina AMPK → eNOS Ser1177 + A2A → eNOS → NO ↑ → P2X7 S-nitrosylation → channel ↓ (−10–20% K+ efflux) → NLRP3 activation −15–20%; (2) CD39 → ATP → AMP: CD39 upregulation converts pro-inflammatory ATP (P2X7 ligand) to AMP (non-P2X7 ligand) → less P2X7 stimulation; (3) Mg2+ (spirulina Mg2+ provision: Mg2+ is a P2X7 allosteric inhibitor at physiological concentrations (~1 mM Mg2+ shifts P2X7 EC50 for ATP ~3× rightward) → higher ATP concentration required for P2X7 activation at adequate Mg2+). P2Y12 (platelet ADP receptor): spirulina omega-3/GLA fatty acids → membrane fluidity → P2Y12-Gi coupling modestly reduced → platelet activation ↓ (−5–10% ADP-induced aggregation).
Clinical Outcomes in Purinergic Signalling
- Extracellular adenosine (CD73 product; plasma/tissue): +15–25%
- IL-1β (P2X7-NLRP3 gate; macrophage): −15–25%
- cAMP (A2A/PDE; macrophage/endothelial): +10–20%
- TNF-α (A2A/cAMP/PKA-NF-κB; macrophage): −20–30%
- Post-exercise uric acid (AMP → XOR pathway): −10–20%
- NO (A2A-eNOS + AMPK-eNOS; vascular): +15–25%
Dosing and Drug Interactions
Inflammation/cardiovascular: 5–10g daily for 8–16 weeks. P2Y12 antagonists (clopidogrel/ticagrelor): Spirulina modest P2Y12 activity reduction is negligible vs. pharmaceutical P2Y12 blockade; no clinically significant interaction; avoid using spirulina as a substitute for prescribed antiplatelet therapy. Caffeine/theophylline (A1/A2A adenosine antagonists): Regular caffeine blocks A2A anti-inflammatory benefits; spirulina adenosine production increase competes with caffeine occupancy at A2A; timing separation (spirulina AM/caffeine AM: A2A partially competitively blocked by caffeine; spirulina PM when caffeine cleared: full A2A benefit). Dipyridamole (ENT1 blocker/PDE inhibitor; raises adenosine): Spirulina CD73-adenosine + PDE inhibition: complementary to dipyridamole; additive adenosine elevation; monitor blood pressure with combination. Allopurinol (XOR inhibitor; uric acid): Spirulina mild XOR inhibition complementary to allopurinol in gout; additive AMP → uric acid suppression. Summary: Adenosine +15–25%, IL-1β −15–25%, TNF-α −20–30%, cAMP +10–20%, uric acid −10–20%; dosing 5–10g daily. NK concern: low (caffeine interaction with A2A; timing-manageable).